Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J5FU
|
|||
| Former ID |
DCL000168
|
|||
| Drug Name |
MIV-701
|
|||
| Indication | Osteoporosis [ICD-11: FB83.0; ICD-10: M85.8] | Discontinued in Phase 1 | [1] | |
| Company |
Medivir
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin K (CTSK) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Lysosome | |||
| Osteoclast differentiation | ||||
| Toll-like receptor signaling pathway | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| Trafficking and processing of endosomal TLR | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | RANKL/RANK Signaling Pathway | |||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016480) | |||
| REF 2 | Medivir designates MIV-710 a Candidate Drug (CD) for Osteoporosis and Osteoarthritis, 2009 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.